Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Experimental Therapeutics

In Vitro Activity of wALADin Benzimidazoles against Different Life Cycle Stages of Plasmodium Parasites

Christian S. Lentz, Julia M. Sattler, Martina Fendler, Simon Gottwalt, Victoria S. Halls, Silke Strassel, Sandra Arriens, Jeffrey S. Hannam, Sabine Specht, Michael Famulok, Ann-Kristin Mueller, Achim Hoerauf, Kenneth M. Pfarr
Christian S. Lentz
aInstitute of Medical Microbiology, Immunology and Parasitology, University Hospital of Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia M. Sattler
bUniversity Hospital Heidelberg, Department for Infectious Diseases, Parasitology Unit, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martina Fendler
aInstitute of Medical Microbiology, Immunology and Parasitology, University Hospital of Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Gottwalt
bUniversity Hospital Heidelberg, Department for Infectious Diseases, Parasitology Unit, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victoria S. Halls
cLIMES Institute, Chemical Biology & Medicinal Chemistry Unit, Universität Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silke Strassel
aInstitute of Medical Microbiology, Immunology and Parasitology, University Hospital of Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Arriens
aInstitute of Medical Microbiology, Immunology and Parasitology, University Hospital of Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey S. Hannam
cLIMES Institute, Chemical Biology & Medicinal Chemistry Unit, Universität Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabine Specht
aInstitute of Medical Microbiology, Immunology and Parasitology, University Hospital of Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Famulok
cLIMES Institute, Chemical Biology & Medicinal Chemistry Unit, Universität Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann-Kristin Mueller
bUniversity Hospital Heidelberg, Department for Infectious Diseases, Parasitology Unit, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Achim Hoerauf
aInstitute of Medical Microbiology, Immunology and Parasitology, University Hospital of Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth M. Pfarr
aInstitute of Medical Microbiology, Immunology and Parasitology, University Hospital of Bonn, Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.02383-14
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

wALADin1 benzimidazoles are specific inhibitors of δ-aminolevulinic acid dehydratase from Wolbachia endobacteria of filarial nematodes. We report that wALADin1 and two derivatives killed blood stage Plasmodium falciparum in vitro (50% inhibitory concentrations, 39, 7.7, and 12.8 μM, respectively). One of these derivatives inhibited gliding motility of Plasmodium berghei ANKA infectious sporozoites with nanomolar affinity and blocked invasion into hepatocytes but did not affect intrahepatocytic replication. Hence, wALADin1 benzimidazoles are tools to study gliding motility and potential antiplasmodial drug candidates.

TEXT

wALADin benzimidazoles are a recently described class of species-specific inhibitors of the heme biosynthesis enzyme δ-aminolevulinic acid dehydratase (ALAD; porphobilinogen synthase) of Wolbachia endobacteria of pathogenic filarial worms (1). The compounds killed filarial nematodes ex vivo in a Wolbachia-dependent manner with no cytotoxicity below 500 µM, thus representing drug lead candidates (1).

The malaria parasite Plasmodium falciparum is able to synthesize heme de novo, suggesting that it is a potential target pathway for new antimalarial drugs (2). P. falciparum uses two forms of ALAD for heme biosynthesis: one is host-derived ALAD (Homo sapiens ALAD [HsALAD]) imported from infected erythrocytes (3), and the second is an endogenous form (PfALAD) (4) targeted to the apicoplast (5). PfALAD accounts for ∼10% of total parasite-derived ALAD activity but may be indispensable during certain life cycle stages or for apicoplast homeostasis (5). In contrast to HsALAD, PfALAD possesses a binding site for allosteric Mg2+ (4) similar to the Wolbachia protein, for which a functional competition with the activation by Mg2+ is part of the inhibitory mechanism (1). We therefore reasoned that wALADins might be effective inhibitors of PfALAD and hence possess antimalarial activity.

To determine the antiplasmodial activity of wALADins, P. falciparum strain 3D7 parasites were cultivated in human blood type A+ erythrocytes under a defined gaseous atmosphere (92% CO2, 3% O2, 5% CO2) at 37°C as published previously (6). Parasitemia was adjusted to 0.2 to 0.5% before the parasites were exposed to 62.5 μM wALADin1 (Fig. 1A, Table 1), the derivatives, or 0.625% dimethyl sulfoxide (DMSO) for 72 h. Compound 1 (wALADin1) and derivatives 4 and 7 reduced parasitemia to nearly 0%, while parasitemia of the DMSO control parasites increased to ∼3% (Fig. 1C). None of the other derivatives had antiplasmodial activity (Fig. 1C). wALADin2, a nonbenzimidazole compound (Fig. 1B) with similar inhibitory activity and mechanism against Wolbachia ALAD (7), was inactive against blood stage P. falciparum (Fig. 1C). Dose-response curves for effective derivatives were very steep (Fig. 1D), and time curve experiments revealed similar progressions of the antiplasmodial effect for all active compounds (Fig. 1E to G). Parasites were killed within 24 to 72 h of exposure to >10 μM compound 4. At lower concentrations, parasite growth was retarded. The corresponding activity profile of wALADin benzimidazoles is shown in Fig. 1H and Table 1. wALADin1 had the weakest activity (50% inhibitory concentration [IC50], 39.3 ± 11.7 μM), while replacement of the R1-3-CF3-benzyl with 4-CF3-benzyl in compound 7 led to an ∼3-fold improvement (IC50, 12.8 ± 0.02 μM). The most potent antiplasmodial compound was compound 4 (IC50, 7.7 ± 1.7 μM), which differs from wALADin1 by repositioning of the R3-COOH from position 5 to 6 of the benzimidazole core. In contrast, derivatives with R3-COOH at position 4 or 7 were inactive. Replacement of either the R1 or R2 moiety with a hydrogen atom abrogated the antiplasmodial activity.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

(A and B) Chemical structures of wALADin1 (A) and wALADin2 (B). (C) wALADin1 and derivatives were tested at 62.5 μM for 72 h in a P. falciparum erythrocyte culture. Parasitemia was determined by counting erythrocytes in blood smears. Chloroquine at 100 nM (CQ) was used as a positive control. Dashed vertical lines separate different experiments. (D) Dose-response curves for wALADin compounds 1, 4, and 7. Curves were fit to a sigmoidal (four-parameter) equation with GraphPad Prism 5.0 [log(inhibitor versus normalized response – variable slope); bottom = 0; top = shared by all data sets]. (E to G) Time course of parasitemia in P. falciparum culture in the presence of wALADin1 (E), compound 4 (F), and compound 7 (G) for 4 days. (H) Structure-activity profile of wALADin1 benzimidazoles in P. falciparum culture. The substituents R1, R2, and R3 are highlighted in gray boxes. Dashed arrows indicate positional changes of substituent groups; continuous arrows indicate replacement with a different chemical group. Arrow or font color indicates an enhancement in antiplasmodial activity (green) or a loss of activity (purple). (I) wALADin1 and compound 4 inhibited replication of T. gondii in LLC-MK2 cells, as determined by real-time PCR, with IC50s 1 order of magnitude (wALADin1) or several orders of magnitude (compound 4) higher than for P. falciparum, indicating specificity of the antiplasmodial effect (D). The graph shows means ± standard errors of the means of results for ≥2 experiments for pyrimethamine and wALADin1 and as means of results for a single experiment for compound 4.

View this table:
  • View inline
  • View popup
TABLE 1

Antiplasmodial activity of wALADin1 benzimidazoles is not correlated with inhibitory activity against PfALAD

To elucidate whether the antiplasmodial effect was due to inhibition of PfALAD, we tested selected derivatives against recombinant PfALAD protein (5) (expression plasmid kindly provided by V. Arun Nagaraj). Enzymatic assays were performed as described previously for orthologs using 250 nM PfALAD in 100 mM Tris-HCl (pH 8.0), 1 mM MgCl2, 200 μM 5-ALA for 60 min (1). wALADin1 and compound 9 showed marginal inhibitory activity at the highest concentration tested (533 μM), whereas neither compound 4 nor 7 was inhibitory (Table 1). Although it may not be ruled out that under physiological conditions the PfALAD may be more susceptible to inhibition, it is likely that the antiplasmodial activity elicited in the one-digit (compound 4) or low two-digit (wALADin1, compound 7) micromolar range is mediated via an alternative target than ALAD.

The specificity of the antiplasmodial effect was tested by determining the activity of wALADins against the related apicomplexan parasite Toxoplasma gondii for which neither wALADin1 nor compound 4 has inhibitory activity against its ALAD ortholog (8). Briefly, LLC-MK2 cells were infected with T. gondii RH strain tachyzoites (multiplicity of infection [MOI], 5). After 2 h, nonadherent parasites were removed by washing and cells were exposed to wALADin1 or compound 4 for 48 h. After DNA extraction from infected cells, tachyzoite numbers were determined by real-time PCR of the T. gondii repeat DNA sequence (GenBank accession no. AF146527.1) normalized to the number of host cells determined by Macaca mulatta β-actin PCR (GenBank Gene ID 574285) (Fig. 1I; Table 2). wALADin1 inhibited T. gondii replication with an IC50 of ∼340 μM; compound 4 had an IC50 between 500 and 1,000 μM. This minor anti-Toxoplasma activity is likely identical to the weak antiproliferative effect on eukaryotic cells previously reported for LLC-MK2 and HEK cells at concentrations of ≥500 μM (1). Thus, the selectivity window of the antiplasmodial effect of compound 4 (IC50, 7.7 μM) over T. gondii and other mammalian cells is ∼100-fold, and the antiplasmodial potency of this compound even exceeds the antifilarial potency of wALADin1 by >10-fold (7).

View this table:
  • View inline
  • View popup
TABLE 2

PCR conditions for T. gondii repeat DNA and M. mulatta β-actin PCRa

To delineate the activity of wALADins against other malarial parasite life cycle stages (sporozoites and liver stages), we used the rodent parasite Plasmodium berghei ANKA. To assess gliding motility, 10,000 infective sporozoites were preincubated with compounds for 15 min on ice. After 30 min of gliding on bovine serum albumin (BSA)-coated glass slides, samples were fixed and gliders and nongliders were differentiated according to the presence or absence of a trail of the major sporozoite surface protein, circumsporozoite protein (CSP), released from the apical end of gliding sporozoites (9). CSP was detected by immunofluorescence microscopy using a Zeiss Axiovert 100M microscope and Zeiss Image Examiner software. Compound 7 dramatically reduced the gliding motility of P. berghei ANKA sporozoites (75% reduction at 200 nM) and completely prevented sporozoites from adhering to glass slides at 40 μM. wALADin1 and compound 4 also prevented sporozoite adhesion at 40 μM but showed no effect on gliding motility at lower concentrations (Fig. 2A). Control compounds 2 and 3 had no effect on sporozoite motility. As gliding motility is required for successful invasion of hepatocytes, we tested whether compound 7 was able to inhibit this important infection process. Sporozoites were preincubated with compound 7 as described above and allowed to invade immortalized human hepatoma cells (Huh7) for 90 min before samples were fixed and stained according to the two-color host cell invasion method (10). Compound 7 blocked sporozoite invasion into hepatoma cells (Fig. 2 B), presumably as a result of suppressed gliding motility. In contrast to invasion into hepatocytes, intrahepatocytic replication was not affected by wALADins at concentrations up to 40 μM (Fig. 2 C and D). alamarBlue cytotoxicity assays with a concentration of 40 μM compound revealed a moderate antiproliferative effect of wALADin1 against Huh7 cells but not of compound 4 or 7, confirming the specificity of the latter compounds. Due to its potent effect on sporozoite gliding motility, we named compound 7 “wALADin-derived inhibitor of Plasmodium motility and invasion1 (ALPin1)” (the chemical structure is shown in Fig. 2E). As a small-molecule tool, ALPin1 may help identify unknown components of the actin-myosin motor-dependent gliding machinery (11, 12).

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

P. berghei ANKA sporozoites were extracted from the salivary glands of infected Anopheles stephensi mosquitoes on days 19 to 23 postinfection, taken up in RPMI medium supplemented with 3% BSA, and used on the same day. (A) Compound 7 potently inhibited the gliding motility of P. berghei ANKA sporozoites. A total of 10,000 sporozoites were added to glass slides precoated with 3% BSA–RPMI medium and allowed to glide for 30 min before fixation with 4% paraformaldehyde–phosphate-buffered saline. Gliding sporozoites were differentiated from adhesive but nongliding sporozoites by a trail of circumsporozoite protein (CSP) detected on the slide by immunofluorescence microsocopy after staining with monoclonal anti-CSP antibody and anti-mouse Alexa Fluor 488 (both at 1:300 in 10% fetal calf serum-PBS) (6). “X” indicates the absence of both sporozoites and CSP trails on the slide. (B) Compound 7 (ALPin1) inhibited the invasion of sporozoites into Huh7 cells. A total of 25,000 cells were seeded onto Lab-Tek 8-well chamber slides 1 day before infection with sporozoites for 90 min (MOI, 0.4). Parasite numbers were determined by fixation and staining using the two-color host cell invasion method. (C and D) For extraerythocytic stage development assays, Huh7 cells were infected with sporozoites for 90 min before free parasites were washed off and compounds were added. Cells were fixed after 24 h, 40 h, or 60 h with ice-cold methanol, followed by staining of liver stage parasites with monoclonal anti-P. berghei HSP70 antibody and goat anti-mouse Alexa Fluor 488 secondary antibody (13). None of the tested wALADins had any effect (up to 40 μM) on the number (C) or the size (D) of liver stage parasites. (E) A total of 6,000 Huh7 cells were seeded onto a 96-well plate before incubation with a 40 μM concentration of the indicated compound or with 0.5% DMSO for 72 h at 37°C and 5% CO2 in triplicate experiments. Neither compound 4 nor compound 7 affected Huh7 cell viability or replication as assessed with alamarBlue reagent. The inhibitor of actin polymerization cytochalasin D (CytD) served as a positive-control inhibitor for motility and invasion studies; primaquine (Pq) was used for intrahepatic stages. NC, negative control. (F) Chemical structure of compound 7 (ALPin1).

In addition to the specificity of the biological effect, the druglike chemical properties of wALADin benzimidazoles, their easy synthetic accessibility, and their steep antiplasmodial activity profile (Fig. 1H) render a future detailed assessment of this compound class as antiplasmodial agents attractive. Validation of these compounds as new antimalarial agents will be completed by target identification using cross-linkable chemical probes based on the chemical scaffold of ALPin1 (compound 7) to identify the molecular target.

ACKNOWLEDGMENTS

We thank V. Arun Nagaran (Department of Biochemistry, Indian Institute of Science, Bangalore, India) for providing the pRSETa-PfALAD expression plasmid and protocol. We thank I. Reiter-Owona and H. Neufeld (Institute for Medical Microbiology, Immunology and Parasitology, University Hospital of Bonn) for supplying T. gondii RH strain tachyzoites.

This work was supported through a grant from the Liverpool School of Tropical Medicine to A.H. and K.M.P as part of the A-WOL Consortium funded by the Bill and Melinda Gates Foundation and through funding from the Deutsche Forschungsgemeinschaft to A.H. and M.F. (SFB 704) and to K.M.P. and A.H. (PF 673/3-2; FOR 854). A.H. is a member of the Cluster of Excellence ImmunoSensation (EXC 1023). J.M.S. is a recipient of the Rahel-Goitein-Strauss-Program of the University Hospital Heidelberg.

FOOTNOTES

    • Received 24 January 2014.
    • Returned for modification 17 April 2014.
    • Accepted 4 September 2014.
    • Accepted manuscript posted online 13 October 2014.
  • Copyright © 2015, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Lentz CS,
    2. Halls V,
    3. Hannam JS,
    4. Niebel B,
    5. Strubing U,
    6. Mayer G,
    7. Hoerauf A,
    8. Famulok M,
    9. Pfarr KM
    . 2013. A selective inhibitor of heme biosynthesis in endosymbiotic bacteria elicits antifilarial activity in vitro. Chem Biol 20:177–187. doi:10.1016/j.chembiol.2012.11.009.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Surolia N,
    2. Padmanaban G
    . 1992. De novo biosynthesis of heme offers a new chemotherapeutic target in the human malarial parasite. Biochem Biophys Res Commun 187:744–750. doi:10.1016/0006-291X(92)91258-R.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Bonday ZQ,
    2. Taketani S,
    3. Gupta PD,
    4. Padmanaban G
    . 1997. Heme biosynthesis by the malarial parasite. Import of delta-aminolevulinate dehydrase from the host red cell. J Biol Chem 272:21839–21846.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Sato S,
    2. Wilson RJ
    . 2002. The genome of Plasmodium falciparum encodes an active delta-aminolevulinic acid dehydratase. Curr Genet 40:391–398. doi:10.1007/s00294-002-0273-3.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Dhanasekaran S,
    2. Chandra NR,
    3. Chandrasekhar Sagar BK,
    4. Rangarajan PN,
    5. Padmanaban G
    . 2004. Delta-aminolevulinic acid dehydratase from Plasmodium falciparum: indigenous versus imported. J Biol Chem 279:6934–6942. doi:10.1074/jbc.M311409200.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Potocnjak P,
    2. Yoshida N,
    3. Nussenzweig RS,
    4. Nussenzweig V
    . 1980. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med 151:1504–1513. doi:10.1084/jem.151.6.1504.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Lentz CS,
    2. Stumpfe D,
    3. Bajorath J,
    4. Famulok M,
    5. Hoerauf A,
    6. Pfarr KM
    . 2013. New chemotypes for wALADin1-like inhibitors of delta-aminolevulinic acid dehydratase from Wolbachia endobacteria. Bioorg Med Chem Lett 23:5558–5562. doi:10.1016/j.bmcl.2013.08.052.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Lentz CS,
    2. Halls VS,
    3. Hannam JS,
    4. Strassel S,
    5. Lawrence SH,
    6. Jaffe EK,
    7. Famulok M,
    8. Hoerauf A,
    9. Pfarr KM
    . 2014. wALADin benzimidazoles differentially modulate the function of porphobilinogen synthase orthologs. J Med Chem 57:2498–2510. doi:10.1021/jm401785n.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Stewart MJ,
    2. Vanderberg JP
    . 1991. Malaria sporozoites release circumsporozoite protein from their apical end and translocate it along their surface. J Protozool 38:411–421. doi:10.1111/j.1550-7408.1991.tb01379.x.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Renia L,
    2. Miltgen F,
    3. Charoenvit Y,
    4. Ponnudurai T,
    5. Verhave JP,
    6. Collins WE,
    7. Mazier D
    . 1988. Malaria sporozoite penetration. A new approach by double staining. J Immunol Methods 112:201–205.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Kappe SH,
    2. Buscaglia CA,
    3. Bergman LW,
    4. Coppens I,
    5. Nussenzweig V
    . 2004. Apicomplexan gliding motility and host cell invasion: overhauling the motor model. Trends Parasitol 20:13–16. doi:10.1016/j.pt.2003.10.011.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Munter S,
    2. Sabass B,
    3. Selhuber-Unkel C,
    4. Kudryashev M,
    5. Hegge S,
    6. Engel U,
    7. Spatz JP,
    8. Matuschewski K,
    9. Schwarz US,
    10. Frischknecht F
    . 2009. Plasmodium sporozoite motility is modulated by the turnover of discrete adhesion sites. Cell Host Microbe 6:551–562. doi:10.1016/j.chom.2009.11.007.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Tsuji M,
    2. Mattei D,
    3. Nussenzweig RS,
    4. Eichinger D,
    5. Zavala F
    . 1994. Demonstration of heat-shock protein 70 in the sporozoite stage of malaria parasites. Parasitol Res 80:16–21. doi:10.1007/BF00932618.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Activity of wALADin Benzimidazoles against Different Life Cycle Stages of Plasmodium Parasites
Christian S. Lentz, Julia M. Sattler, Martina Fendler, Simon Gottwalt, Victoria S. Halls, Silke Strassel, Sandra Arriens, Jeffrey S. Hannam, Sabine Specht, Michael Famulok, Ann-Kristin Mueller, Achim Hoerauf, Kenneth M. Pfarr
Antimicrobial Agents and Chemotherapy Dec 2014, 59 (1) 654-658; DOI: 10.1128/AAC.02383-14

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Activity of wALADin Benzimidazoles against Different Life Cycle Stages of Plasmodium Parasites
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Activity of wALADin Benzimidazoles against Different Life Cycle Stages of Plasmodium Parasites
Christian S. Lentz, Julia M. Sattler, Martina Fendler, Simon Gottwalt, Victoria S. Halls, Silke Strassel, Sandra Arriens, Jeffrey S. Hannam, Sabine Specht, Michael Famulok, Ann-Kristin Mueller, Achim Hoerauf, Kenneth M. Pfarr
Antimicrobial Agents and Chemotherapy Dec 2014, 59 (1) 654-658; DOI: 10.1128/AAC.02383-14
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596